Sunitinib produces neuroprotective effect via inhibiting nitric oxide overproduction

CNS Neuroscience and Therapeutics

Volumn 20, Issue 3, 2014, Pages 244-252

  Cui, Wei ^a,b   Zhang, Zai Jun ^a,c,d   Hu, Sheng Quan ^a,b   Mak, Shing Hung ^a,b   Xu, Da Ping ^a,b   Choi, Chung Lit ^a   Wang, Yu Qiang ^d   Tsim, Wah Keung ^e   Lee, Ming Yuen ^c   Rong, Jian Hui ^f   Han, Yi Fan ^a,b  

^a HONG KONG POLYTECHNIC UNIVERSITY   (Hong Kong)

^b The Hong Kong Polytechnic University Shenzhen Research Institute   (Hong Kong)

^c University of Macau   (Macao)

^d JINAN UNIVERSITY   (China)

^e HONG KONG UNIVERSITY OF SCIENCE AND TECHNOLOGY   (Hong Kong)

^f THE UNIVERSITY OF HONG KONG   (Hong Kong)

Author keywords

Cancer; Neuroprotection; Nitric oxide; Nitric oxide synthase; Receptor tyrosine kinase; Sunitinib

Indexed keywords

NITRATE; NITRIC OXIDE; NITRIC OXIDE SYNTHASE; NITRITE; POTASSIUM; SHORT HAIRPIN RNA; SUNITINIB;

APOPTOSIS; ARTICLE; CELL VIABILITY; COLORIMETRY; CONTROLLED STUDY; CYTOTOXICITY; ENZYME ACTIVITY; ENZYME INHIBITION; GRANULE CELL; HUMAN; HUMAN CELL; MTT ASSAY; NERVE CELL NECROSIS; NEUROPROTECTION; NEUROTOXICITY; PROTEIN EXPRESSION;

CANCER; NEUROPROTECTION; NITRIC OXIDE; NITRIC OXIDE SYNTHASE; RECEPTOR TYROSINE KINASE; SUNITINIB;

1-METHYL-4-PHENYL-1,2,3,6-TETRAHYDROPYRIDINE; ANIMALS; ANIMALS, NEWBORN; APOPTOSIS; CELLS, CULTURED; CEREBELLUM; DOSE-RESPONSE RELATIONSHIP, DRUG; ENZYME INHIBITORS; GENE EXPRESSION REGULATION; HUMANS; INDAZOLES; INDOLES; NEURONS; NEUROPROTECTIVE AGENTS; NEUROTOXINS; NITRIC OXIDE; OMEGA-N-METHYLARGININE; PYRROLES; RATS; RATS, SPRAGUE-DAWLEY;

EID: 84894236810     PISSN: 17555930     EISSN: 17555949     Source Type: Journal    
DOI: 10.1111/cns.12203     Document Type: Article

References (36)

1. Rock EP, Goodman V, Jiang JX, et al. Food and Drug Administration drug approval summary: sunitinib malate for the treatment of gastrointestinal stromal tumor and advanced renal cell carcinoma. Oncologist 2007;12:107-113.
2. Adams VR, Leggas M. Sunitinib malate for the treatment of metastatic renal cell carcinoma and gastrointestinal stromal tumors. Clin Ther 2007;29:1338-1353.
3. Sun L, Tran N, Tang F, et al. Synthesis and biological evaluations of 3-substituted indolin-2-ones: a novel class of tyrosine kinase inhibitors that exhibit selectivity toward particular receptor tyrosine kinases. J Med Chem 1998;41:2588-2603.
4. Faivre S, Demetri G, Sargent W, Raymond E. Molecular basis for sunitinib efficacy and future clinical development. Nat Rev Drug Discov 2007;6:734-745.
5. Patyna S, Peng G. Distribution of sunitinib and its active metabolite in brain and spinal cord tissue following oral or intravenous administration in rodents and monkeys. Eur J Cancer Suppl 2006;12:21.
6. Van der Veldt AA, Van den Eertwegh AJ, Hoekman K, Barkhof F, Boven E. Reversible cognitive disorders after sunitinib for advanced renal cell cancer in patients with preexisting arteriosclerotic leukoencephalopathy. Ann Oncol 2007;18:1747-1750.
7. Medioni J, Cojocarasu O, Belcaceres JL, Halimi P, Oudard S. Complete cerebral response with sunitinib for metastatic renal cell carcinoma. Ann Oncol 2007;18:1282-1283.
8. Addeo R, Caraglia M. The oral tyrosine kinase inhibitors lapatinib and sunitinib: new opportunities for the treatment of brain metastases from breast cancer? Expert Rev Anticancer Ther 2011;11:139-142.
9. Tang SC, Lagas JS, Lankheet NA, et al. Brain accumulation of sunitinib is restricted by P-glycoprotein (ABCB1) and breast cancer resistance protein (ABCG2) and can be enhanced by oral elacridar and sunitinib coadministration. Int J Cancer 2012;130:223-233.
10. Cui W, Zhang Z, Li W, et al. Unexpected neuronal protection of SU5416 against 1-Methyl-4-phenylpyridinium ion-induced toxicity via inhibiting neuronal nitric oxide synthase. PLoS One 2012;7:e46253.
11. Cui W, Zhang Z, Li W, et al. The anti-cancer agent SU4312 unexpectedly protects against MPP(+) -induced neurotoxicity via selective and direct inhibition of neuronal NOS. Br J Pharmacol 2013;168:1201-1214.
12. Cui W, Li W, Han R, et al. PI3-K/Akt and ERK pathways activated by VEGF play opposite roles in MPP+-induced neuronal apoptosis. Neurochem Int 2011;59:945-953.
13. Nait Oumesmar B, Vignais L, Baron-Van Evercooren A. Developmental expression of platelet-derived growth factor alpha-receptor in neurons and glial cells of the mouse CNS. J Neurosci 1997;17:125-139.
14. Manova K, Bachvarova RF, Huang EJ, et al. c-kit receptor and ligand expression in postnatal development of the mouse cerebellum suggests a function for c-kit in inhibitory interneurons. J Neurosci 1992;12:4663-4676.
15. Li W, Pi R, Chan HH, et al. Novel dimeric acetylcholinesterase inhibitor bis7-tacrine, but not donepezil, prevents glutamate-induced neuronal apoptosis by blocking N-methyl-D-aspartate receptors. J Biol Chem 2005;280:18179-18188.
16. Cohen PS, Chan JP, Lipkunskaya M, Biedler JL, Seeger RC. Expression of stem cell factor and c-kit in human neuroblastoma. The Children's Cancer Group. Blood 1994;84:3465-3472.
17. Mohan N, Karmakar S, Banik NL, Ray SK. SU5416 and EGCG work synergistically and inhibit angiogenic and survival factors and induce cell cycle arrest to promote apoptosis in human malignant neuroblastoma SH-SY5Y and SK-N-BE2 cells. Neurochem Res 2011;36:1383-1396.
18. Hynds DL, Summers M, Van Brocklyn J, O'Dorisio MS, Yates AJ. Gangliosides inhibit platelet-derived growth factor-stimulated growth, receptor phosphorylation, and dimerization in neuroblastoma SH-SY5Y cells. J Neurochem 1995;65:2251-2258.
19. Wu F, Poon WS, Lu G, et al. Alpha-synuclein knockdown attenuates MPP+ induced mitochondrial dysfunction of SH-SY5Y cells. Brain Res 2009;1292:173-179.
20. Li W, Xue J, Niu C, et al. Synergistic neuroprotection by bis(7)-tacrine via concurrent blockade of N-methyl-D-aspartate receptors and neuronal nitric-oxide synthase. Mol Pharmacol 2007;71:1258-1267.
21. Sheng JZ, Wang D, Braun AP. DAF-FM (4-amino-5-methylamino-2′, 7′-difluorofluorescein) diacetate detects impairment of agonist-stimulated nitric oxide synthesis by elevated glucose in human vascular endothelial cells: reversal by vitamin C and L-sepiapterin. J Pharmacol Exp Ther 2005;315:931-940.
22. Mahairaki V, Xu L, Farah MH, et al. Targeted knock-down of neuronal nitric oxide synthase expression in basal forebrain with RNA interference. J Neurosci Methods 2009;179:292-299.
23. Fu H, Dou J, Li W, et al. Mecamylamine prevents neuronal apoptosis induced by glutamate and low potassium via differential anticholinergic-independent mechanisms. Neuropharmacology 2008;54:755-765.
24. Przedborski S, Jackson-Lewis V, Yokoyama R, Shibata T, Dawson VL, Dawson TM. Role of neuronal nitric oxide in 1-methyl-4-phenyl-1, 2, 3, 6-tetrahydropyridine (MPTP)-induced dopaminergic neurotoxicity. Proc Natl Acad Sci U S A 1996;93:4565-4571.
25. Hantraye P, Brouillet E, Ferrante R, et al. Inhibition of neuronal nitric oxide synthase prevents MPTP-induced parkinsonism in baboons. Nat Med 1996;2:1017-1021.
26. Zhang L, Smith KM, Chong AL, et al. In vivo antitumor and antimetastatic activity of sunitinib in preclinical neuroblastoma mouse model. Neoplasia 2009;11:426-435.
27. Roskoski R Jr. Sunitinib: a VEGF and PDGF receptor protein kinase and angiogenesis inhibitor. Biochem Biophys Res Commun 2007;356:323-328.
28. Wood JM, Bold G, Buchdunger E, et al. PTK787/ZK 222584, a novel and potent inhibitor of vascular endothelial growth factor receptor tyrosine kinases, impairs vascular endothelial growth factor-induced responses and tumor growth after oral administration. Cancer Res 2000;60:2178-2189.
29. Bobba A, Atlante A, Moro L, Calissano P, Marra E. Nitric oxide has dual opposite roles during early and late phases of apoptosis in cerebellar granule neurons. Apoptosis 2007;12:1597-1610.
30. Yeste-Velasco M, Folch J, Trullas R, et al. Glycogen synthase kinase-3 is involved in the regulation of the cell cycle in cerebellar granule cells. Neuropharmacology 2007;53:295-307.
31. Ma C, Ying C, Yuan Z, et al. dp5/HRK is a c-Jun target gene and required for apoptosis induced by potassium deprivation in cerebellar granule neurons. J Biol Chem 2007;282:30901-30909.
32. Gonzalez-Polo RA, Soler G, Fuentes JM. MPP+: mechanism for its toxicity in cerebellar granule cells. Mol Neurobiol 2004;30:253-264.
33. Aparicio LM, Pulido EG, Gallego GA. Sunitinib-induced asthenia: from molecular basis to clinical relief. Cancer Biol Ther 2011;12:765-771.
34. Oo TF, Kholodilov N, Burke RE. Regulation of natural cell death in dopaminergic neurons of the substantia nigra by striatal glial cell line-derived neurotrophic factor in vivo. J Neurosci 2003;23:5141-5148.
35. Sariola H, Saarma M. Novel functions and signalling pathways for GDNF. J Cell Sci 2003;116:3855-3862.
36. Kramer ER, Aron L, Ramakers GM, et al. Absence of Ret signaling in mice causes progressive and late degeneration of the nigrostriatal system. PLoS Biol 2007;5:e39.